[Platelets aggregation employing ADP and cephalin. Comparative tests (author's transl)]. 1976

F Ottaviani, and E Pagani

The AA. have carried out researches into the results of the platelets aggregation test (PAT) on 375 people by use of the Born method; they have employed ADP and a commercial available cephalin (Thrombofax, Ortho). In the first case the parameters taken into consideration are: the minimum dose of ADP able to cause a "double wave aggregation", the slope and the maximum increase in light transmission; in the second case the parameters considered are: the latency period, the maximum speed and the maximum amplitude. The normal values, in 75 persons, are: --6 +/- 2 X 10(-7)M (min dose wor "double wave"); --15,5 +/- 4,9 UT/min (slope); -- 46,3 +/- 6,8 UT (max increase in light transmission); regarding ADP aggregation. --90 +/- 40 sec (latency period); -- 30 +/- 15 UT/min (max speed); -- 52 +/- 4,63 UT (max amplitude); relating to Thrombofax aggregation. Analyses of PAT, by parallel using both aggregating agents, have been made on 260 women undergoina an oestrogen-progestative therapy, on 25 daibetic subjects and on 15 subjects undergoing an anti-aggregation oral therapy (Ageroplas, Serono, Roma). The AA. stress on the validity of ADP as an aggregation agent in routine tests, while Trombofax has revealed itself to be not very sensitive in all the cases with hyperaggregation. However it is to be noted that use of cephalin results interesting in tests made on subjects undergoing an anti-aggregation therapy, as the PAT parameters seen proportional to the quantity of the drug given to the patient, which is just the opposite of what happens with ADP.

UI MeSH Term Description Entries
D008297 Male Males
D010714 Phosphatidylethanolamines Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to an ethanolamine moiety. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid and ethanolamine and 2 moles of fatty acids. Cephalin,Cephalins,Ethanolamine Phosphoglyceride,Ethanolamine Phosphoglycerides,Ethanolamineglycerophospholipids,Phosphoglyceride, Ethanolamine,Phosphoglycerides, Ethanolamine
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D003925 Diabetic Angiopathies VASCULAR DISEASES that are associated with DIABETES MELLITUS. Diabetic Vascular Complications,Diabetic Vascular Diseases,Microangiopathy, Diabetic,Angiopathies, Diabetic,Angiopathy, Diabetic,Diabetic Angiopathy,Diabetic Microangiopathies,Diabetic Microangiopathy,Diabetic Vascular Complication,Diabetic Vascular Disease,Microangiopathies, Diabetic,Vascular Complication, Diabetic,Vascular Complications, Diabetic,Vascular Disease, Diabetic,Vascular Diseases, Diabetic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000244 Adenosine Diphosphate Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position. ADP,Adenosine Pyrophosphate,Magnesium ADP,MgADP,Adenosine 5'-Pyrophosphate,5'-Pyrophosphate, Adenosine,ADP, Magnesium,Adenosine 5' Pyrophosphate,Diphosphate, Adenosine,Pyrophosphate, Adenosine
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000925 Anticoagulants Agents that prevent BLOOD CLOTTING. Anticoagulant Agent,Anticoagulant Drug,Anticoagulant,Anticoagulant Agents,Anticoagulant Drugs,Anticoagulation Agents,Indirect Thrombin Inhibitors,Agent, Anticoagulant,Agents, Anticoagulant,Agents, Anticoagulation,Drug, Anticoagulant,Drugs, Anticoagulant,Inhibitors, Indirect Thrombin,Thrombin Inhibitors, Indirect

Related Publications

F Ottaviani, and E Pagani
October 1980, Radiobiologia, radiotherapia,
F Ottaviani, and E Pagani
June 1977, Quaderni Sclavo di diagnostica clinica e di laboratorio,
F Ottaviani, and E Pagani
June 1979, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
F Ottaviani, and E Pagani
January 1982, Aktuelle Gerontologie,
F Ottaviani, and E Pagani
July 1981, [Rinsho ketsueki] The Japanese journal of clinical hematology,
F Ottaviani, and E Pagani
August 1973, Casopis lekaru ceskych,
F Ottaviani, and E Pagani
October 1980, La Nouvelle presse medicale,
F Ottaviani, and E Pagani
May 1973, Thrombosis et diathesis haemorrhagica,
F Ottaviani, and E Pagani
January 1968, Vox sanguinis,
Copied contents to your clipboard!